WolverHeme Happy Hour

In this episode, Anthony and Bernie are joined by special guest, Dr. Justin Kaner from Weill Cornell Medicine, to discuss some of the most interesting ASH abstracts in leukemia in 2025! What abstracts should change practice? Listen to find out. Some of the abstracts discussed:PARADIGM: https://meetings-api.hematology.org/api/abstract/vmpreview/296881KMT2A Outcomes (MARROW Consortium and Othman, et al.): https://meetings-api.hematology.org/api/abstract/vmpreview/302582 and https://meetings-api.hematology.org/api/abstract/vmpreview/297333CLIA +/- Ven: https://meetings-api.hematology.org/api/abstract/vmpreview/302047FLT3i studies (and MRD): https://meetings-api.hematology.org/api/abstract/vmpreview/295719 and https://meetings-api.hematology.org/api/abstract/vmpreview/302699 and https://meetings-api.hematology.org/api/abstract/vmpreview/291322ALL GIMEMA Trial (blin + ponatinib): https://meetings-api.hematology.org/api/abstract/vmpreview/296532Menin inhibitor data

Anthony and Bernie discuss the PARADIGM study that was presented at the plenary session of ASH 2025 and whether results should change our practice. https://meetings-api.hematology.org/api/abstract/vmpreview/296881

In this study, Bernie and Anthony are joined by the majestic myeloma man Manni Mohyuddin to discuss key ASH abstracts in myeloma, including the results of the MajesTEC-3 study!

In this episode, Anthony and Bernie discuss the important role of community hematology. We discuss innovative research models, partnerships between community and academic practices, and ways to improve care for hematology patients who live near and far!

In this episode, Bernie and Anthony review the optimal management of febrile neutropenia! We talk about some historical data, optimal patient workup, proper selection of antibiotics, and a discussion of newer data regarding early antibiotic de-escalation in FN.

We're back after a summer break! In this episode, Anthony and Bernie review the optimal approach to antimicrobial prophylaxis in hematology patients. How do you best choose prophylaxis for your patients? Where are we using data and where are we just making things up? Does everyone need antifungal, antibacterial, antiviral, and anti-PJP prophylaxis? We will demystify prophylaxis guidelines for you!

In this episode, Bernie and Anthony talk about some BIG changes in cytarabine dosing in AML consolidation after a recent practice changing article. Will this change your practice? Hunault, et al. NEJM. 2025.https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400326

In this episode, Bernie and Anthony are joined by the Myeloma Man Dr. Manni Mohyuddin and lymphoma expert Dr. David Russler-Germain to discuss the very recent ODAC decisions on the STARGLO (glofitamab + GemOx) and AQUILA (daratumumab for smoldering multiple myeloma) trials. Did ODAC do their due diligence, or are there double standards? There is a lot to unpack in this episode!

This is a special encore video presentation of Anthony and Bernie teaming up with the Common Sense Oncology Journal Club series to discuss the SWOG1826 and STARGLO clinical trials. Tycel Phillips, MD, and Manju Sengar, MD join Anthony and Bernie for a great discussion of the trials and how they should impact practice! Join the Common Sense Oncology movement here! https://commonsenseoncology.org/

Joining the discussion are Victoria Nachar, an outpatient hematology pharmacist from the University of Michigan with expertise in lymphoma and myeloma, and James Davis, a malignant hematology pharmacist and assistant professor at MUSC, known for his deep knowledge in multiple myeloma. They explore the management of cytokine release syndrome (CRS) in patients receiving bispecific antibodies, comparing it to CAR-T therapies. They discuss current treatment strategies, the role of prophylactic tocilizumab, and the importance of tailored approaches in patient care.